Jazz Pharma Announces Health Canada Approval Of Sunosi - Quick Facts

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced the Health Canada approval and availability of Sunosi for the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Sunosi is a dopamine and norepinephrine reuptake inhibitor. The approval of Sunosi is based on data from a phase 3 clinical program which enrolled over 1,500 adults in four randomized placebo-controlled studies.

In 2014, the company acquired a license to develop and commercialize Sunosi from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to Sunosi, excluding certain jurisdictions in Asia.